BLRX News Alert Biolinerx Ltd (BLRX) 1.87 02/14/2015 11:45:3

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 12:45 PM

Biolinerx Ltd (BLRX) 1.87 $BLRX

Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ADNC: 4.59 (-0.02), AHT: 10.63 (-0.04), ABY: 34.40 (+0.08), ACGL: 59.95 (+0.36), BLRX: 1.87 (-0.02)

Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
CPF: 23.66 (+0.02), RESI: 17.99 (-0.24), CMPR: 84.38 (-0.39), ABY: 34.40 (+0.08), BLRX: 1.87 (-0.02)

BioLineRx to Present at 2015 BIO CEO & Investor Conference in New York on February 10
Business Wire - Tue Feb 03, 6:01AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present a company update at the 2015 BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 09:00 a.m. EST. The conference will be held at the Waldorf Astoria Hotel in New York.
BLRX: 1.87 (-0.02)

ARIAD's Iclusig Endorsed by EC for All Approved Indications - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 1:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) announced that the European Commission endorsed the CHMP's recommendation on the use of Iclusig in its approved indications.
ENDP: 84.01 (+1.12), ARIA: 7.35 (+0.45), BIOD: 1.38 (-0.14), BLRX: 1.87 (-0.02)

VBL Therapeutics Announces Ron Cohen and Philip Serlin Nominated to Board of Directors
GlobeNewswire - Tue Jan 20, 7:12AM CST
VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory disease, today announced the nomination of industry veterans Ron Cohen, M.D., and Philip Serlin, C.P.A. to stand for election to the Board of Directors at VBL's extraordinary general meeting of shareholders, scheduled for February 11, 2015. Both individuals currently are leaders of biotechnology companies publicly traded in the US: Dr. Cohen serves as the President and Chief Executive Officer of Acorda Therapeutics, Inc. (Nasdaq:ACOR) and Mr. Serlin is Chief Financial and Operating Officer of BioLineRx Ltd. (Nasdaq:BLRX).
ACOR: 36.14 (-0.51), VBLT: 14.11 (+0.24), DYAX: 15.00 (-0.16), BLRX: 1.87 (-0.02)

Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
KMX: 67.68 (+1.10), TECH: 94.61 (+1.83), AL: 38.65 (+0.27), ABGB: 15.52 (+0.34), BLRX: 1.87 (-0.02)

BioLineRx Announces Completion of Enrollment in CE Mark Registration Trial of BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction
Business Wire - Wed Jan 14, 7:15AM CST
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that patient enrollment has been completed in Bellerophon's PRESERVATION I pivotal CE Mark registration trial of BL-1040, currently named Bioabsorbable Cardiac Matrix (BCM), a novel resorbable polymer solution for the prevention of cardiac remodeling following an acute myocardial infarction (AMI).
BLRX: 1.87 (-0.02)

BioLineRx Finishes Dose-Escalation in Phase I BL-8040 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 12:40PM CST
BioLineRx Ltd. (BLRX) completed the dose-escalation stage in a phase I study on BL-8040 for the mobilization of stem cells.
SHPG: 239.82 (+6.11), APRI: 1.84 (-0.08), BIOD: 1.38 (-0.14), BLRX: 1.87 (-0.02)

BioLineRx Completes Dose Escalation Stage of Phase 1 Trial for Novel Stem Cell Mobilization Treatment
Business Wire - Tue Jan 06, 7:01AM CST
--- Multiple additional clinical milestones for BL-8040 anticipated in 2015 -
BLRX: 1.87 (-0.02)

BioLineRx to Present at Biotech Showcase 2015 Conference in San Francisco
Business Wire - Tue Jan 06, 6:01AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham Union Square Hotel in San Francisco, CA.
BLRX: 1.87 (-0.02)

BioLineRx Out-Licences Skin Lesion Treatment Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 2:15PM CST
BioLineRx (BLRX) out-licenced BL-5010 in Europe, Australia and additional countries to Omega Pharma.
MDCO: 29.79 (+0.91), AMGN: 153.48 (+0.30), BLRX: 1.87 (-0.02), NVS: 102.20 (-0.17)

BioLineRx out-licenses dermatology drug
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:29PM CST

BLRX: 1.87 (-0.02)

BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma
Business Wire - Tue Dec 23, 3:00PM CST
--- First product expected to reach the market in 2016 -
BLRX: 1.87 (-0.02)

Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.44 (-0.01), ASPX: 65.76 (+2.76), MDVN: 104.71 (+0.67), CYCC: 0.62 (-0.01), OPK: 13.80 (-0.28), NLNK: 38.84 (+1.51), JUNO: 40.52 (+0.18), REGN: 402.40 (+0.66), MYGN: 34.03 (+0.40), PFE: 34.64 (-0.23), IMGN: 7.19 (unch), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), BLRX: 1.87 (-0.02), OREX: 5.55 (+0.10), DVA: 73.10 (-3.29), BLCM: 20.00 (-0.81), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), GERN: 3.03 (unch), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)

BioLineRx teams up with Novartis
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 6:33AM CST

BLRX: 1.87 (-0.02), NVS: 102.20 (-0.17)

BioLineRx and Major Global Pharmaceutical Company Form Strategic Collaboration for Screening and Development of Novel Drug Candidates
Business Wire - Tue Dec 16, 6:00AM CST
--- BioLineRx to host conference call today, December, 16 at 10:00 a.m. EST -
BLRX: 1.87 (-0.02), NVS: 102.20 (-0.17)

BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform
Business Wire - Fri Dec 12, 6:00AM CST
--- Development strategy presented today at BioLineRx investor meeting in New York -
BLRX: 1.87 (-0.02)

BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference
Business Wire - Mon Dec 08, 6:00AM CST
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that data from the on-going Phase 2a clinical trial of BL-8040 for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) were reported at the American Society of Hematology (ASH) meeting, held on December 6-9, 2014, in San Francisco.
BLRX: 1.87 (-0.02)

BioLineRx net loss improves in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:17AM CST

BLRX: 1.87 (-0.02)

Biolinerx EPS of -NIS0.08
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:18AM CST

BLRX: 1.87 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JiMMYBAR! Unveils World's First Creatine Trail Mix

The New Face of Snacking: Creatine Trail Mix I'll tell you right off the bat, JiMMYBAR! seems to be cornering the snack world with an odd—but interesting—twist. They've just launched the world's first Creatine + Protein Trail Mix, blending muscle-building nutrients with the classic crunch of trail mix. Sounds quirky, and it’s exclusive to their site, JiMMYBARs.com....

Jaguar Promise Tackles College Cost for Texas Students

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

xFusion Tackles Cooling and Power at OCP 2026

Bracing for an AI Revolution Ah, the world of AI — it's like the wild west out there, with data centers struggling to keep up as workloads skyrocket. Enter xFusion, a veteran in the computing infrastructure game, rolling out some seriously impressive tech at the 2026 Open Compute Project (OCP) Global Summit. The company's latest offering showcases how they're tackling...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

AI-Powered Travel Transformation in Norway Revealed

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

Laars Welcomes Women in Manufacturing to Facility Tour

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...